Total Payments
$3,094
2024 Payments
$36.00
Companies
18
Transactions
170
Medicare Patients
2,019
Medicare Billing
$1.6M
Payment Breakdown by Category
Food & Beverage$3,000 (97.0%)
Consulting$50.00 (1.6%)
Education$44.19 (1.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,000 | 164 | 97.0% |
| Consulting Fee | $50.00 | 1 | 1.6% |
| Education | $44.19 | 5 | 1.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $595.85 | 26 | $0 (2024) |
| PFIZER INC. | $428.53 | 38 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $306.27 | 15 | $0 (2020) |
| Celgene Corporation | $241.22 | 8 | $0 (2019) |
| UCB, Inc. | $219.91 | 8 | $0 (2019) |
| Genentech USA, Inc. | $187.40 | 11 | $0 (2019) |
| GlaxoSmithKline, LLC. | $179.57 | 8 | $0 (2019) |
| AbbVie Inc. | $147.61 | 8 | $0 (2021) |
| Janssen Biotech, Inc. | $147.12 | 9 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $118.70 | 8 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $36.00 | 1 | Amgen Inc. ($36.00) |
| 2021 | $24.87 | 2 | AbbVie Inc. ($13.37) |
| 2020 | $122.54 | 7 | PFIZER INC. ($37.57) |
| 2019 | $993.36 | 47 | Celgene Corporation ($168.49) |
| 2018 | $920.56 | 61 | Amgen Inc. ($183.25) |
| 2017 | $997.15 | 52 | Amgen Inc. ($216.89) |
All Payment Transactions
170 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/11/2024 | Amgen Inc. | Prolia (Biological) | Food and Beverage | In-kind items and services | $36.00 | General |
| Category: Bone Health | ||||||
| 08/03/2021 | AbbVie Inc. | RINVOQ (Biological), HUMIRA | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: IMMUNOLOGY | ||||||
| 08/02/2021 | Amgen Inc. | AVSOLA (Biological), Enbrel | Food and Beverage | In-kind items and services | $11.50 | General |
| Category: Inflammation | ||||||
| 03/10/2020 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $15.72 | General |
| Category: Immunology | ||||||
| 03/03/2020 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), STELARA | Food and Beverage | In-kind items and services | $20.12 | General |
| Category: Immunology | ||||||
| 02/25/2020 | Horizon Therapeutics plc | RAYOS (Drug), RAYOS, RAYOS | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: RAYOS | ||||||
| 02/18/2020 | Merck Sharp & Dohme Corporation | RENFLEXIS (Biological) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: IMMUNOLOGY | ||||||
| 02/11/2020 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: IMMUNOLOGY | ||||||
| 01/21/2020 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $21.98 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 01/14/2020 | PFIZER INC. | INFLECTRA (Biological) | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: INFLAMMATION | ||||||
| 12/10/2019 | Genentech USA, Inc. | Rituxan (Biological), Actemra | Food and Beverage | In-kind items and services | $20.14 | General |
| Category: BioOncology/Immunology | ||||||
| 12/04/2019 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $30.06 | General |
| 12/03/2019 | PFIZER INC. | CELEBREX (Drug), LYRICA | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: INFLAMMATION;ONCOLOGY;PAIN | ||||||
| 11/19/2019 | Lilly USA, LLC | TALTZ (Drug), OLUMIANT | Food and Beverage | In-kind items and services | $13.67 | General |
| Category: Immunology | ||||||
| 11/12/2019 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $34.83 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2019 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $20.00 | General |
| 11/04/2019 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $7.23 | General |
| Category: Inflammation | ||||||
| 10/29/2019 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $12.59 | General |
| Category: Immunology | ||||||
| 10/22/2019 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $27.08 | General |
| Category: Immunology | ||||||
| 10/08/2019 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), STELARA | Food and Beverage | In-kind items and services | $15.29 | General |
| Category: Immunology | ||||||
| 10/01/2019 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: Inflammation | ||||||
| 09/24/2019 | AbbVie, Inc. | Rinvoq (Biological) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: Immunology | ||||||
| 09/17/2019 | Horizon Therapeutics plc | RAYOS (Drug), RAYOS, RAYOS | Food and Beverage | In-kind items and services | $17.72 | General |
| Category: RAYOS | ||||||
| 09/10/2019 | Merck Sharp & Dohme Corporation | RENFLEXIS (Biological) | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: IMMUNOLOGY | ||||||
| 09/03/2019 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 15 | 897 | 58,241 | $1.8M | $661,514 |
| 2020 | 18 | 1,122 | 20,797 | $2.5M | $888,513 |
Total Patients
2,019
Total Services
79,038
Medicare Billing
$1.6M
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2021 | 17 | 46,800 | $421,200 | $292,888 | 69.5% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2021 | 45 | 7,610 | $1.1M | $259,805 | 22.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 31 | 2,040 | $44,200 | $32,669 | 73.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 251 | 391 | $57,714 | $31,621 | 54.8% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 54 | 191 | $48,705 | $21,984 | 45.1% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2021 | 54 | 221 | $15,470 | $5,421 | 35.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 71 | 83 | $8,076 | $4,157 | 51.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 17 | 65 | $16,575 | $3,721 | 22.4% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 50 | 280 | $19,780 | $3,139 | 15.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 17 | 17 | $3,385 | $2,258 | 66.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 17 | 17 | $4,305 | $1,950 | 45.3% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2021 | 15 | 19 | $1,332 | $889.66 | 66.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 172 | 230 | $762.00 | $687.00 | 90.2% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2021 | 19 | 25 | $967.40 | $184.48 | 19.1% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2021 | 67 | 252 | $5,040 | $139.78 | 2.8% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2020 | 49 | 12,760 | $1.9M | $533,491 | 27.9% |
| J9312 | Injection, rituximab, 10 mg | Office | 2020 | 11 | 2,600 | $286,000 | $193,426 | 67.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 28 | 2,700 | $58,500 | $41,390 | 70.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 284 | 521 | $58,143 | $38,939 | 67.0% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 60 | 315 | $80,325 | $34,632 | 43.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 154 | 206 | $15,914 | $9,337 | 58.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 20 | 155 | $39,525 | $8,717 | 22.1% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2020 | 60 | 353 | $24,780 | $8,413 | 34.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 51 | 51 | $10,710 | $7,494 | 70.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 24 | 27 | $5,560 | $4,395 | 79.0% |
About Dr. Cameron Jones, MD
Dr. Cameron Jones, MD is a Rheumatology healthcare provider based in Kansas City, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720043078.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cameron Jones, MD has received a total of $3,094 in payments from pharmaceutical and medical device companies, with $36.00 received in 2024. These payments were reported across 170 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($3,000).
As a Medicare-enrolled provider, Jones has provided services to 2,019 Medicare beneficiaries, totaling 79,038 services with total Medicare billing of $1.6M. Data is available for 2 years (2020–2021), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Kansas City, MO
- Active Since 04/19/2006
- Last Updated 07/30/2012
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1720043078
Products in Payments
- Enbrel (Biological) $362.16
- COSENTYX (Biological) $306.27
- XELJANZ (Drug) $258.39
- Cimzia (Drug) $219.91
- Otezla (Drug) $197.60
- BENLYSTA (Biological) $155.18
- Rituxan (Biological) $122.54
- ORENCIA (Biological) $118.70
- Humira (Biological) $115.92
- SIMPONI ARIA (Biological) $106.53
- KEVZARA (Drug) $93.20
- INFLECTRA (Biological) $84.71
- KRYSTEXXA (Drug) $80.21
- RAYOS (Drug) $77.74
- LYRICA (Drug) $70.82
- Actemra (Biological) $64.86
- ACTHAR (Biological) $62.50
- FORTEO (Drug) $55.93
- RENFLEXIS (Biological) $48.95
- REMICADE (Biological) $40.59
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Kansas City
Dr. Mark Box, Md, MD
Rheumatology — Payments: $461,914
Rheumatology $461,914
Thomas Scott, M.d, M.D
Rheumatology — Payments: $163,330
Rheumatology $163,330
John Ervin, Md, MD
Rheumatology — Payments: $130,602
Rheumatology $130,602
Dr. Shashank Radadiya, Md, MD
Rheumatology — Payments: $95,431
Rheumatology $95,431
Ghaith Noaiseh, Md, MD
Rheumatology — Payments: $21,392
Rheumatology $21,392
Dr. David John, Md, MD
Rheumatology — Payments: $1,325
Rheumatology $1,325